Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309268 | 1.00 | RECQL (0.53) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL5678234 | 1.00 | RECQL (0.53) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL11310912 | 0.84 | RECQL (0.67) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL28568575 | 0.84 | RECQL (0.56) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL2910667 | 0.84 | RECQL (0.67) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL2910666 | 0.84 | RECQL (0.67) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL28997303 | 0.83 | AKR1C3 (0.50) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| Hydrochloric Acid SCHEMBL11747959 | 0.82 | RECQL (0.65) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL4949275 | 0.82 | RECQL (0.47) | RECQLAKR1C3GRIK1GRIK2MTNR1A | |
| SCHEMBL4952660 | 0.82 | RECQL (0.47) | RECQLAKR1C3GRIK1GRIK2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118831211-A | Lubricating coating with anti-hyperplasia effect and preparation method thereof | 四川大学华西医院 | 2024-10-25 | — | — | CN | claimed |
| CN-118702096-A | Method for recycling battery negative electrode graphite, regenerated graphite material prepared by method and application of regenerated graphite material | 广东邦普循环科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118593783-A | Super hydrophilic coating with anticoagulation anti-inflammatory performance and preparation method thereof | 四川大学华西医院 | 2024-09-06 | — | — | CN | claimed |
| CN-118576785-A | Super-lubricating coating with super-hydrophobic performance and preparation method thereof | 四川大学华西医院 | 2024-09-03 | — | — | CN | claimed |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-12-22 | — | — | US | claimed |
| US-20090297496-A1 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases | CHILDRENS HOSPITAL MEDICAL CENTER (US) | 2009-12-03 | — | — | US | claimed |
| WO-2007030375-A2 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-03-15 | — | — | WO | claimed |
| EP-1653939-A2 | METHOD FOR TREATING CACHEXIA WITH RETINOID LIGANDS | Allergan, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005013949-A2 | METHOD FOR TREATING CACHEXIA WITH RETINOID LIGANDS | ALLERGAN, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-6365186-B1 | ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT | GELTEX PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | claimed |
| WO-2000069445-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| CN-118831211-A | Lubricating coating with anti-hyperplasia effect and preparation method thereof | 四川大学华西医院 | 2024-10-25 | — | — | CN | disclosed |
| CN-118702096-A | Method for recycling battery negative electrode graphite, regenerated graphite material prepared by method and application of regenerated graphite material | 广东邦普循环科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118593783-A | Super hydrophilic coating with anticoagulation anti-inflammatory performance and preparation method thereof | 四川大学华西医院 | 2024-09-06 | — | — | CN | disclosed |
| CN-118576785-A | Super-lubricating coating with super-hydrophobic performance and preparation method thereof | 四川大学华西医院 | 2024-09-03 | — | — | CN | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297496-A1 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases | LIPC, PNLIP, LIPA | RECQL 2712/4885AKR1C3 1030/4885GRIK1 3671/4885 |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | RECQL 2712/4885AKR1C3 1030/4885GRIK1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.